Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Michael Amantea"'
Autor:
Weiwei Tan, Kourosh Parivar, Keith D. Wilner, Michael Amantea, Reza Khosravan, Akintunde Bello, Dana J. Nickens, Erjian Wang
Supplementary Table and Development of the population PK model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c63f2ef81252a959212330340b58133
https://doi.org/10.1158/1078-0432.22467297.v1
https://doi.org/10.1158/1078-0432.22467297.v1
Autor:
Weiwei Tan, Kourosh Parivar, Keith D. Wilner, Michael Amantea, Reza Khosravan, Akintunde Bello, Dana J. Nickens, Erjian Wang
Purpose: We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUCss) following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a06274236be1b2a0878cdd6cd60f0f8
https://doi.org/10.1158/1078-0432.c.6526605.v1
https://doi.org/10.1158/1078-0432.c.6526605.v1
Publikováno v:
Investigational New Drugs. 36:121-135
Background Antibody drug conjugates (ADCs) utilize a monoclonal antibody to deliver a cytotoxic payload specifically to tumor cells, limiting exposure to healthy tissues. Major clinical toxicities of ADCs include hematologic, hepatic, neurologic, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c506bc51cc62662d18d26ce65dfb53
https://doi.org/10.1007/s10637-017-0520-6
https://doi.org/10.1007/s10637-017-0520-6
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:373-382
The relationships between exposure, biomarkers (vascular endothelial growth factor (VEGF), soluble VEGF receptors (sVEGFR)-1, -2, -3, and soluble stem cell factor receptor (sKIT)), tumor sum of longest diameters (SLD), diastolic blood pressure (dBP),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a94de520307f7d82ee8c1884ccd22fa4
https://doi.org/10.1002/psp4.12193
https://doi.org/10.1002/psp4.12193
Publikováno v:
Drug metabolism and pharmacokinetics. 34(2)
This article [1] has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the authors. According to the authors, their recent analyses ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d697035dec760c37adb21823dde64f56
https://pubmed.ncbi.nlm.nih.gov/24919837
https://pubmed.ncbi.nlm.nih.gov/24919837
Publikováno v:
Cancer Research. 75:P5-19
Background: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor that blocks G1/S cell cycle progression. The current population analysis assessed the effect of palbociclib exposure on QT interval and heart rate (via evaluation of RR inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28d2171f8fb6f327fd608df97c9ccd8e
https://doi.org/10.1158/1538-7445.sabcs14-p5-19-16
https://doi.org/10.1158/1538-7445.sabcs14-p5-19-16
Publikováno v:
British Journal of Clinical Pharmacology. 77:480-492
AIMS Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma. The objectives of this analysis were to assess plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67be768a53f6c47eb078b3baf3ecbb1d
https://doi.org/10.1111/bcp.12206
https://doi.org/10.1111/bcp.12206
Autor:
May Garrett, Timothy J. Taylor, Michael Amantea, Diane R. Mould, Ying Chen, Yazdi K. Pithavala, Antonella Ingrosso
Publikováno v:
Cancer chemotherapy and pharmacology. 78(6)
Axitinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors 1–3, is approved for second-line treatment of advanced renal cell carcinoma. Axitinib is partially metabolized by cytochrome P450 1A2, which is induced by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95f1ca2750381061210b3f6501091f02
https://pubmed.ncbi.nlm.nih.gov/27783139
https://pubmed.ncbi.nlm.nih.gov/27783139
Autor:
Akintunde Bello, Keith D. Wilner, Erjian Wang, Michael Amantea, Reza Khosravan, Kourosh Parivar, Weiwei Tan, Dana J. Nickens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(23)
Purpose: We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUCss) following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb9011b3b5963bec988a2097b23f47c
https://pubmed.ncbi.nlm.nih.gov/27281559
https://pubmed.ncbi.nlm.nih.gov/27281559
Publikováno v:
Clinical Pharmacology & Therapeutics. 83:153-159
To assess the QTc prolongation by ritonavir (RTV) 100 mg and explore its potential use as CYP3A inhibitor in thorough QTc (TQT) studies. Randomized, crossover study of single-dose RTV 100 mg, placebo, and moxifloxacin (MFLX) 400 mg in 65 healthy subj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55788b19408f76c160bbb422a4197730
https://doi.org/10.1038/sj.clpt.6100263
https://doi.org/10.1038/sj.clpt.6100263